Skip to main content
. 2019 Sep 12;16(9):e1002901. doi: 10.1371/journal.pmed.1002901

Fig 1. Trial profile.

Fig 1

Participants were recruited from June 2013 to March 2016 and were randomised to either once-daily recombinant human interleukin-1-receptor antagonist (100 mg of anakinra) by daily subcutaneous self-administration or TNFi administered according to relevant data sheets. TNFi, tumour necrosis factor inhibitor.